The MHA-TP (microhemagglutination assay for Treponema pallidum) is a treponemal blood test designed to detect antibodies the immune system produces specifically in response to the syphilis-causing bacterium. Unlike nontreponemal tests that pick up general markers of tissue damage, MHA-TP confirms whether a person’s immune system has encountered T. pallidum itself. Although once a mainstay confirmatory test in syphilis diagnosis, its sensitivity gaps and the arrival of newer alternatives have largely pushed it out of routine clinical use, making its story worth understanding for anyone navigating syphilis testing today.
How the MHA-TP Test Works
The test relies on a straightforward immunological principle. Red blood cells from sheep are coated with antigens derived from Treponema pallidum, the spirochete bacterium that causes syphilis. When a patient’s serum is added to these sensitized cells, any treponemal antibodies present will bind to the antigens on the cell surface. That binding causes the red blood cells to clump together visibly, a reaction called hemagglutination. A technician reads the result by looking at the pattern of cells in a microtiter plate well: clumped cells mean the test is reactive (positive), while cells that settle into a tight button at the bottom mean it is nonreactive (negative).
To guard against false positives, the test includes a control step. Unsensitized red blood cells, ones not coated with T. pallidum antigens, are run alongside the sensitized cells. If a patient’s serum causes clumping in both the sensitized and the unsensitized wells, the result is considered nonspecific and cannot be interpreted as a true positive. This control helps filter out cases where antibodies in the blood are reacting to the sheep cells themselves rather than to syphilis antigens.
Because MHA-TP targets antibodies specific to T. pallidum, it falls into the category of treponemal tests, as distinct from nontreponemal tests like RPR or VDRL that detect antibodies against lipid material released during tissue damage. Treponemal tests are generally more specific for syphilis but also more expensive and labor-intensive to perform than their nontreponemal counterparts.1Clinical Microbiology Reviews. Laboratory diagnosis and interpretation of tests for syphilis
Sensitivity Across Stages of Syphilis
One of the most clinically important things to understand about MHA-TP is that its accuracy varies dramatically depending on when in the course of infection you test. Syphilis progresses through distinct stages, and the immune response the test relies on takes time to develop fully.
In primary syphilis, the earliest stage marked by the appearance of a chancre, MHA-TP performs relatively poorly. Its sensitivity has been reported between roughly 46% and 89%, meaning it can miss anywhere from one in ten to more than half of confirmed primary syphilis cases. That is a wide and troubling range. By comparison, FTA-ABS (the fluorescent treponemal antibody absorption test) catches about 78% to 100% of primary cases, and TP-PA (the T. pallidum particle agglutination assay) catches about 86% to 100%.2PubMed Central. Sensitivity and Specificity of Treponemal-specific Tests for the Diagnosis of Syphilis
The picture improves for secondary syphilis, the stage where the bacterium has spread more widely and the immune response is stronger. Here, MHA-TP sensitivity rises to 90% to 100%, which is closer to the performance of FTA-ABS and TP-PA. For early latent syphilis, all three manual treponemal assays perform similarly, with sensitivities in the range of about 94% to 100%. Late latent disease, however, sees a slight dip across the board, with sensitivities ranging from roughly 85% to 100%.3Clinical Infectious Diseases. Sensitivity and Specificity of Treponemal-specific Tests for the Diagnosis of Syphilis
The bottom line from aggregated data is that among the manual treponemal assays, MHA-TP consistently demonstrated the poorest sensitivity across all stages of syphilis.2PubMed Central. Sensitivity and Specificity of Treponemal-specific Tests for the Diagnosis of Syphilis This is particularly relevant in early infection, where catching cases quickly matters most for preventing transmission and complications.
Why Primary Syphilis Is So Hard to Catch
The weak performance of MHA-TP in primary syphilis is not entirely the test’s fault. At the earliest stage of infection, the body simply has not had enough time to mount a robust antibody response. Treponemal tests like MHA-TP depend on detectable levels of IgG and IgM antibodies directed against T. pallidum. In the first few weeks after exposure, those antibody levels may be too low for hemagglutination to occur, producing a false-negative result even in a genuinely infected person.
This is a practical concern because primary syphilis is the stage when people are most likely to seek testing. They notice a painless sore, or a partner discloses an infection, and they go to a clinic. If the test used for confirmation has a sensitivity as low as 46% at that moment, a large number of true cases will be told they are negative. Those people may then unknowingly transmit the infection to others during what becomes secondary syphilis.
Other treponemal assays do somewhat better in this early window, likely because they use different detection methods that can pick up lower concentrations of antibodies. FTA-ABS, for instance, uses fluorescent microscopy, which amplifies the signal. TP-PA uses gelatin particles rather than red blood cells, which may agglutinate more readily at low antibody concentrations. These differences in assay design translate directly into clinical sensitivity differences that matter for patient care.
False Positives and What Triggers Them
Treponemal tests like MHA-TP are generally quite specific for syphilis, meaning a positive result usually indicates genuine exposure to T. pallidum. But “quite specific” is not “perfect,” and a handful of conditions can produce misleading reactive results.
The best-documented cause of false-positive treponemal results is autoimmune disease, particularly systemic lupus erythematosus. In a study examining sera from lupus patients, a small number of samples were reactive on MHA-TP, though the titers were low.4JAMA Dermatology. Borderline and Reactive FTA-ABS Results in Lupus Erythematosus This happens because autoimmune conditions produce a wide array of aberrant antibodies, some of which cross-react with treponemal antigens. Low titers in such cases can be an important clue that the result is a biological false positive rather than evidence of syphilis.
Other infections caused by related spirochete bacteria can also trigger positive treponemal results. Lyme disease, caused by Borrelia burgdorferi, is the most commonly cited example. Yaws, pinta, and endemic syphilis, all caused by other Treponema subspecies, will reliably produce positive results on MHA-TP and other treponemal tests because the antigens are nearly identical. In regions where these infections are endemic, a reactive treponemal result cannot automatically be attributed to sexually transmitted syphilis.
The control step built into MHA-TP (testing against unsensitized cells) catches some nonspecific reactivity, but it cannot distinguish between antibodies produced by venereal syphilis and antibodies produced by yaws or another treponematosis. That distinction often comes down to clinical history and epidemiological context rather than the laboratory result alone.
How MHA-TP Fits Into Syphilis Diagnostic Algorithms
Syphilis diagnosis has never relied on a single test. Instead, clinicians use algorithms that combine nontreponemal and treponemal tests in a defined sequence. The two main approaches are known as the traditional algorithm and the reverse algorithm.
In the traditional algorithm, a nontreponemal test like RPR or VDRL is used as the initial screen. If that screen is reactive, the sample then goes to a treponemal test for confirmation. MHA-TP historically served as one of the confirmatory options in this second step. The logic is straightforward: nontreponemal tests are cheap and easy to run in bulk but produce a fair number of false positives, so a treponemal confirmatory test filters those out.5PubMed Central. The Traditional or Reverse Algorithm for Diagnosis of Syphilis: Pros and Cons
The reverse algorithm flips the order. An automated treponemal test is used as the initial screen, and reactive samples are followed up with a nontreponemal test. This approach has become increasingly popular in large-volume laboratories because the initial treponemal screen can be run on automated platforms that process hundreds of samples without manual interpretation. When the two tests disagree, a second treponemal test from a different assay class is sometimes used as a tiebreaker.
MHA-TP could theoretically serve in either algorithm, but its manual nature and lower sensitivity have made it a poor fit for the high-throughput demands of modern screening laboratories. Even in its heyday, it was primarily a confirmatory test rather than a screening tool.
The Shift Away From MHA-TP
MHA-TP was widely used through the 1980s and 1990s, but it has been progressively replaced in clinical practice for several reasons. The most direct replacement is TP-PA, which works on a similar agglutination principle but uses gelatin particles instead of sheep red blood cells. TP-PA offers better sensitivity, particularly in early syphilis, and has fewer issues with nonspecific reactivity from the carrier particles.
Beyond TP-PA, the bigger shift in syphilis diagnostics has been toward fully automated platforms. Chemiluminescence immunoassays (CLIAs) and enzyme immunoassays (EIAs) can screen large batches of samples with minimal hands-on labor and produce objective, instrument-read results rather than relying on a technician’s visual interpretation of a microtiter plate. Evaluations of automated CLIA platforms have found excellent diagnostic sensitivity and specificity when used as screening tests for syphilis, performing comparably to manual TP-PA and offering the advantage of high-throughput automation.6PubMed. Evaluation of two automated chemiluminescence immunoassays, the LIAISON Treponema Screen and the ARCHITECT Syphilis TP, and the Treponema pallidum particle agglutination test for laboratory diagnosis of syphilis
This matters because syphilis screening volumes have increased substantially in recent years as rates of infection have risen in many countries. A test that requires manual setup, visual reading, and individual interpretation does not scale well in a lab processing thousands of samples per day. The economics and logistics of modern laboratory medicine have made MHA-TP essentially obsolete in high-income settings, even though the test remains perfectly functional in principle.
You may still encounter MHA-TP referenced in older medical literature, historical patient records, or in settings with limited access to automated platforms. Understanding what it measures and where its limitations lie remains relevant for interpreting those results correctly.
Neurosyphilis and Cerebrospinal Fluid Testing
Syphilis can invade the central nervous system at any stage, producing a condition called neurosyphilis. Diagnosing it typically requires analyzing cerebrospinal fluid (CSF) obtained through a lumbar puncture. The standard CSF test for neurosyphilis has long been the CSF-VDRL, a nontreponemal test. It is quite specific when reactive, but its sensitivity is limited, meaning a negative CSF-VDRL does not rule out neurosyphilis.
MHA-TP was not commonly used on CSF, but its successor TP-PA has been studied in this context. Research has found that a CSF-TPPA titer at or above a certain threshold showed high diagnostic specificity comparable to CSF-VDRL, and it identified additional neurosyphilis cases that CSF-VDRL missed. In one validation study, using CSF-TPPA alongside CSF-VDRL would have increased the number of neurosyphilis diagnoses by about a fifth.7PubMed Central. Cerebrospinal Fluid Treponema pallidum Particle Agglutination Assay for Neurosyphilis Diagnosis
This finding underscores the broader theme in syphilis diagnostics: no single test catches everything. Combining tests from different assay classes, treponemal and nontreponemal, remains the most reliable strategy, whether you are testing blood or spinal fluid. The evolution from MHA-TP to TP-PA has not changed that fundamental principle, but it has improved the sensitivity of the treponemal component.
Congenital Syphilis and Diagnostic Challenges in Newborns
One area where syphilis testing becomes particularly complicated is in newborns born to mothers who test positive for syphilis. Congenital syphilis, infection passed from mother to fetus, can cause severe and lasting harm, including bone deformities, hearing loss, and neurological damage. But diagnosing it in an asymptomatic newborn is notoriously difficult.
The core problem is that maternal antibodies, both treponemal and nontreponemal, cross the placenta. A newborn’s blood may test positive on MHA-TP, TP-PA, RPR, or any other syphilis test simply because the baby is carrying its mother’s antibodies, not because the baby is infected. Distinguishing passively transferred maternal antibodies from the infant’s own immune response requires careful comparison of maternal and newborn test results, physical examination for subtle clinical signs, and sometimes additional workup including CSF analysis and X-rays.8Seminars in Pediatric Infectious Diseases. Congenital syphilis
In practice, clinicians look at whether the infant’s nontreponemal titer is significantly higher than the mother’s, which would suggest active infection in the baby. They also assess whether the mother received adequate treatment during pregnancy and how early in pregnancy treatment began. A treponemal test like MHA-TP or TP-PA alone cannot answer the question of whether a newborn is actively infected, because it will be reactive from maternal antibodies regardless. This is another context where understanding what the test actually measures, and what it cannot tell you, prevents misinterpretation.
What a Reactive Treponemal Test Means Years Later
One feature of treponemal tests that sometimes confuses patients and even clinicians is that they typically remain reactive for life, even after successful treatment. If you had syphilis, were treated with antibiotics, and were cured, your MHA-TP (or TP-PA, or any other treponemal test) will almost certainly still come back positive years or decades later. This does not mean you still have syphilis. It means your immune system retains the antibody memory of having encountered T. pallidum.
Nontreponemal tests, by contrast, usually decline after successful treatment and may eventually become nonreactive. This is why nontreponemal titers (RPR or VDRL titers) are used to monitor treatment response and detect reinfection: a rising titer after treatment suggests new or persistent infection, while a falling titer indicates the treatment is working.
For someone with a history of treated syphilis, a reactive treponemal test paired with a nonreactive or low-titer nontreponemal test is the expected pattern. It is not cause for alarm and does not warrant retreatment. However, this lifelong reactivity means treponemal tests are poor tools for distinguishing past from current infection. If you move to a new doctor or get tested at a new clinic, your treponemal screen will light up, and it becomes important to communicate your treatment history so that a reactive result is not mistaken for new disease.
When You Might Still Encounter MHA-TP
Although MHA-TP has been phased out of routine use in most modern laboratories, it has not vanished entirely. Some reference laboratories in resource-limited settings still use it, and older reagent stocks may still be in circulation. If you are reviewing medical records from the 1980s or 1990s, you will frequently see MHA-TP listed alongside RPR or VDRL results as part of a standard syphilis workup.
Interpreting an old MHA-TP result follows the same logic as interpreting any treponemal test. A reactive result indicates exposure to T. pallidum at some point but does not distinguish active from past infection and does not indicate the stage of disease. A nonreactive result, particularly if the sample was drawn during early primary syphilis, does not reliably exclude infection given the test’s sensitivity limitations during that stage.
For current clinical practice, if your lab report shows a treponemal result, it is far more likely to be TP-PA, a CLIA, or an EIA than MHA-TP. But the interpretive framework is the same across all treponemal assays: they confirm exposure to the organism, they stay positive for life, and they need to be paired with nontreponemal test results and clinical context to guide treatment decisions. The shift from MHA-TP to newer assays improved sensitivity and laboratory efficiency, but it did not change the fundamental role treponemal tests play in the diagnostic puzzle.